Long-Term Safety of Oral Transmucosal Fentanyl Citrate for Breakthrough Cancer Pain Richard Payne, MD, Paul Coluzzi, MD, Lowell Hart, MD, Mary Simmonds,

Slides:

Advertisements

Similar presentations

The Relationship Between Depression and Pain Language in Cancer and Chronic Non- Cancer Pain Patients Thomas C. Sist, DDS, Gerard A. Florio, PhD, Marguerite.

Advertisements

Oropharyngeal Mucositis Pain Treatment with Transdermal Buprenorphine in Patients After Allogeneic Stem Cell Transplantation Samuel Vokurka, MD, PhD

Safety, Tolerability and Symptom Outcomes Associated with l-Carnitine Supplementation in Patients with Cancer, Fatigue, and Carnitine Deficiency: A Phase.

Managing Metastatic Bone Pain: The Role of Bisphosphonates

Managing Metastatic Bone Pain: The Role of Bisphosphonates

Insights Into the Reluctance of Patients With Late-Stage Cancer to Adopt Exercise as a Means to Reduce Their Symptoms and Improve Their Function Andrea.

An Assessment of the Safety, Eff icacy, and Acceptability of Intranasal Fentanyl Citrate in the Management of Cancer-Related Breakthrough Pain Giovambattista.

Effects of High Dose Opioids and Sedatives on Survival in Terminally Ill Cancer Patients Tatsuya Morita, MD, Junichi Tsunoda, MD, Satoshi Inoue, MD,

An Effective Treatment of Severe Complex Regional Pain Syndrome Type 1 in a Child Using High Doses of Intrathecal Ziconotide Michael Stanton-Hicks, MD,

A Case Series of Patients Using Medicinal Marihuana for Management of Chronic Pain Under the Canadian Marihuana Medical Access Regulations Mary E. Lynch,

Opioids for Cancer Breakthrough Pain: A Pilot Study Reporting Patient Assessment of Time to Meaningful Pain Relief Giovambattista Zeppetella, FRCP Journal.

Edmonton, Canada: A Regional Model of Palliative Care Development

Anita L Comley, PhD, RN, AOCN, Elaine DeMeyer, RN, MSN, AOCN

Development of a self-report screening instrument for assessing potential opioid medication misuse in chronic pain patients Laura L Adams, PhD, Robert.

Use of the Cumulative Proportion of Responders Analysis Graph to Present Pain Data Over a Range of Cut-Off Points: Making Clinical Trial Data More Understandable

Oropharyngeal Mucositis Pain Treatment with Transdermal Buprenorphine in Patients After Allogeneic Stem Cell Transplantation Samuel Vokurka, MD, PhD

Bettina N. Nielsen, MSc, Gitte Aagaard, RN, Steen W

Fentanyl Pectin Nasal Spray Versus Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Comparative.

Geographic Variation in Hospice Use in the United States in 2002

David M. Dosa, MD, MPH, David D

Inpatient Palliative Care and Patient Pain: Pre- and Post-Outcomes

Polyanalgesic consensus conference 2003: an update on the management of pain by intraspinal drug delivery— report of an expert panel Samuel J Hassenbusch,

Transdermal Fentanyl for Chronic Pain in AIDS

The Opioid Rotation Ratio From Transdermal Fentanyl to “Strong” Opioids in Patients With Cancer Pain Akhila Reddy, MD, Sriram Yennurajalingam, MD, MS,

David Clark, PhD, Michael Wright, PhD

Redefining Appropriate Treatment Expectations

When Patients Lack Capacity: The Roles That Patients with Terminal Diagnoses Would Choose for Their Physicians and Loved Ones in Making Medical Decisions

Development of a Cancer Pain Prognostic Scale

Equipping medical students to manage cancer pain: A comparison of three educational methods Paul A. Sloan, MD, Margaret Plymale, RN, Pat LaFountain,

Measurement of QTc in Patients Receiving Chronic Methadone Therapy

Characterization of the early pharmacodynamic profile of oral methadone for cancer- related breakthrough pain: a pilot study Kim Fisher, PhD, Carla Stiles,

L-Carnitine Supplementation in Patients with Advanced Cancer and Carnitine Deficiency: A Double-Blind, Placebo-Controlled Study Ricardo A. Cruciani,

Jodi L. Hannan, MD, Steven M. Radwany, MD, Terry Albanese, PhD

Paul A. Sloan, MD, Dwight E. Moulin, MD, FRCP(C), Helen Hays, MD

Evaluation of Methadone Absorption After Topical Administration to Hospice Patients Robert K. Sylvester, PharmD, Caroline Schauer, RN, John Thomas, MD,

A Pilot Randomized Controlled Trial of an Oral Care Intervention to Reduce Mucositis Severity in Stem Cell Transplant Patients Prisco Salvador, RN, MScN,

Factors Related to Adherence to Opioids in Black Patients With Cancer Pain Katherine A. Yeager, PhD, RN, FAAN, Bryan Williams, PhD, Jinbing Bai, PhD,

The effect of transdermal fentanyl treatment on serum cortisol concentrations in patients with non-cancer pain Emine Ozyuvaci, MD, Nergis Yanmaz Alnigenis,

Robert L. Jayes, MD, Robert M. Arnold, MD, Erik K. Fromme, MD

Prevalence and Characteristics of Breakthrough Pain in Cancer Patients Admitted to a Hospice Giovambattista Zeppetella, BSc (Hons), MRCGP, Catherine.

Evaluation of the FICA Tool for Spiritual Assessment

Methadone Analgesia in Cancer Pain Patients on Chronic Methadone Maintenance Therapy Paolo L Manfredi, MD, Gilbert R Gonzales, Andrea L Cheville, Craig.

Cancer Pain Education Journal of Pain and Symptom Management

Transdermal Fentanyl in Opioid-Naive Cancer Pain Patients

U.S. Hospice Benefits Journal of Pain and Symptom Management

The Spiritual Needs Assessment for Patients (SNAP): Development and Validation of a Comprehensive Instrument to Assess Unmet Spiritual Needs Rashmi K.

No evidence for sex differences in the severity and treatment of cancer pain Janet M. Edrington, RN, MS, Steven Paul, PhD, Marylin Dodd, RN, PhD, Claudia.

Barriers to Cancer Pain Relief

The impact of demographic and disease-specific variables on pain in cancer patients Tone Rustøen, RN, PhD, Sophie D Fosså, MD, Dr Med Sci, Jon Skarstein,

Development and Reliability Testing of the Victoria Bowel Performance Scale (BPS) G. Michael Downing, MD, Craig Kuziemsky, PhD, Mary Lesperance, PhD,

Longitudinal Quality of Life in Advanced Cancer Patients

The Impact of Delirium on the Circadian Distribution of Breakthrough Analgesia in Advanced Cancer Patients Bruno Gagnon, MD, Peter G. Lawlor, MB, Isabelle.

Comparative Efficacy of Oral Extended-Release Hydromorphone and Immediate- Release Hydromorphone in Patients with Persistent Moderate to Severe Pain: Two.

Carmen R. Green, MD, Laura Montague, BS, Tamera A. Hart-Johnson, MS

Clinical and Economic Impact of Palliative Care Consultation

Ketamine Use for Reduction of Opioid Tolerance in a 5-Year-Old Girl with End-Stage Abdominal Neuroblastoma Doralina L. Anghelescu, MD, Linda L. Oakes,

Physical Function in Patients with Cancer

Safety, Tolerability and Symptom Outcomes Associated with l-Carnitine Supplementation in Patients with Cancer, Fatigue, and Carnitine Deficiency: A Phase.

Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness: A Double-Blind, Randomized, Parallel.

Gerd Inger Ringdal, PhD, Marit S Jordhøy, MD, Stein Kaasa, PhD

Multidimensional independent predictors of cancer-related fatigue

Optimizing Decision Making and Resource Allocation in Palliative Care

Development of a Brief Assessment Scale for Caregivers of the Medically Ill Myra Glajchen, DSW, Alice Kornblith, PhD, Peter Homel, PhD, Lisa Fraidin,

Economic Evaluation of the Fentanyl Transdermal System for the Treatment of Chronic Moderate to Severe Pain Deirdre M Neighbors, BA, Timothy J Bell,

Efficacy and Safety of a Six-Hour Continuous Overlap Method for Converting Intravenous to Transdermal Fentanyl in Cancer Pain Renato V. Samala, MD, Rafael.

The Association of Depression and Pain with Health-Related Quality of Life, Disability, and Health Care Use in Cancer Patients Kurt Kroenke, MD, Dale.

Is It the Difference a Day Makes

Cancer Symptom Clusters: A Validation Study

Use of oral and transdermal opioids among patients with metastatic cancer during the last year of life Ariel Berger, MPH, Ellen Dukes, PhD, RN, Meredith.

The Patient Care Travelling Record© in Palliative Care

Presentation transcript:

Long-Term Safety of Oral Transmucosal Fentanyl Citrate for Breakthrough Cancer Pain Richard Payne, MD, Paul Coluzzi, MD, Lowell Hart, MD, Mary Simmonds, MD, Alan Lyss, MD, Richard Rauck, MD, Robert Berris, MD, Michael A Busch, PhD, Earl Nordbrook, PhD, Diane B Loseth, RN, MSN, Russell K Portenoy, MD Journal of Pain and Symptom Management Volume 22, Issue 1, Pages 575-583 (July 2001) DOI: 10.1016/S0885-3924(01)00306-2

Fig. 1 Number of Days Patients Used OTFC (n = 151) Journal of Pain and Symptom Management 2001 22, 575-583DOI: (10.1016/S0885-3924(01)00306-2)

Fig. 2 Number of OTFC Units Per Patient (n = 151) Journal of Pain and Symptom Management 2001 22, 575-583DOI: (10.1016/S0885-3924(01)00306-2)

Fig. 3 Initial Dose of OTFC in Relation to Initial Dose of Around-the-Clock Medication for Patients Using Transdermal Fentanyl (n = 53) and Patients Using Oral Opioids (n = 99) Journal of Pain and Symptom Management 2001 22, 575-583DOI: (10.1016/S0885-3924(01)00306-2)